IO Biotech expands collaboration with MSD – begins phase II trial

IO Biotech is initiating a third clinical collaboration with partner MSD to develop a combination treatment for three types of cancer, comprised of MSD's blockbuster drug Keytruda and IO Biotech's lead candidate. A phase II trial is on its way, and should it prove successful, IO Biotech will maintain global commercial rights.
Mai-Britt Zocca, CEO and founder of IO Biotech, has signed off on the Danish cancer company's third deal with US-based MSD | Photo: IO Biotech / PR
Mai-Britt Zocca, CEO and founder of IO Biotech, has signed off on the Danish cancer company's third deal with US-based MSD | Photo: IO Biotech / PR
by albert rønning-andersson, translated by daniel pedersen

Danish cancer company IO Biotech is entering its third clinical collaboration with US-based pharmaceutical giant MSD. The ambition is to develop a drug for the treatment of three different types of cancer, it reports in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading